JP3617668B2 - 麻疹ウイルス組換え体ポックスウイルスワクチン - Google Patents

麻疹ウイルス組換え体ポックスウイルスワクチン Download PDF

Info

Publication number
JP3617668B2
JP3617668B2 JP50520492A JP50520492A JP3617668B2 JP 3617668 B2 JP3617668 B2 JP 3617668B2 JP 50520492 A JP50520492 A JP 50520492A JP 50520492 A JP50520492 A JP 50520492A JP 3617668 B2 JP3617668 B2 JP 3617668B2
Authority
JP
Japan
Prior art keywords
virus
plasmid
recombinant
vaccinia
measles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP50520492A
Other languages
English (en)
Japanese (ja)
Other versions
JPH06502996A (ja
Inventor
パオレッティ，エンゾ
テイラー，ジル
Original Assignee
ヴァイロジェネティクス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァイロジェネティクス コーポレイション filed Critical ヴァイロジェネティクス コーポレイション
Publication of JPH06502996A publication Critical patent/JPH06502996A/ja
Application granted granted Critical
Publication of JP3617668B2 publication Critical patent/JP3617668B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP50520492A 1990-11-20 1991-11-20 麻疹ウイルス組換え体ポックスウイルスワクチン Expired - Fee Related JP3617668B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62161490A 1990-11-20 1990-11-20
US621,614 1990-11-20
US77686791A 1991-10-22 1991-10-22
US776,867 1991-10-22
PCT/US1991/008703 WO1992008789A1 (en) 1990-11-20 1991-11-20 Measles virus recombinant poxvirus vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2004170929A Division JP3824619B2 (ja) 1990-11-20 2004-06-09 麻疹ウイルス組換え体ポックスウイルスワクチン

Publications (2)

Publication Number Publication Date
JPH06502996A JPH06502996A (ja) 1994-04-07
JP3617668B2 true JP3617668B2 (ja) 2005-02-09

Family

ID=27089007

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50520492A Expired - Fee Related JP3617668B2 (ja) 1990-11-20 1991-11-20 麻疹ウイルス組換え体ポックスウイルスワクチン
JP2004170929A Expired - Fee Related JP3824619B2 (ja) 1990-11-20 2004-06-09 麻疹ウイルス組換え体ポックスウイルスワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2004170929A Expired - Fee Related JP3824619B2 (ja) 1990-11-20 2004-06-09 麻疹ウイルス組換え体ポックスウイルスワクチン

Country Status (12)

Country Link
JP (2) JP3617668B2 (enExample)
AU (1) AU1253892A (enExample)
BE (1) BE1005908A5 (enExample)
CA (1) CA2096633A1 (enExample)
CH (1) CH683921A5 (enExample)
DE (2) DE4192786T1 (enExample)
FR (1) FR2669346B1 (enExample)
GB (2) GB2264949B (enExample)
IE (2) IE68404B1 (enExample)
IT (1) IT1252687B (enExample)
NL (2) NL195058C (enExample)
WO (1) WO1992008789A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US6248333B1 (en) 1990-04-04 2001-06-19 Health Research Inc. Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD)
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
JP3602530B2 (ja) * 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
WO1992016616A1 (en) * 1991-03-20 1992-10-01 Virogenetics Corporation Malaria recombinant poxvirus vaccine
EP0592546B1 (en) * 1991-06-14 2003-05-28 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
CN1089370C (zh) * 1994-12-08 2002-08-21 中国预防医学科学研究院病毒学研究所 表达麻疹病毒l4株血凝素及融合蛋白基因的重组痘苗病毒
AU2118997A (en) * 1996-02-05 1997-08-22 Johns Hopkins University, The Measles immunization by dna transcription unit inoculation
AU750322B2 (en) 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
EP1095948A1 (en) * 1999-10-28 2001-05-02 Universitätsklinikum Freiburg Idiotype vaccines
AU2002252199B2 (en) * 2001-03-08 2008-01-03 Emory University MVA expressing modified HIV envelope, GAG, and POL genes
AR052743A1 (es) * 2006-04-11 2007-03-28 Inst Nac De Tecnologia Agropec Vector plasmidico de transferencia y virus canarypox recombinante

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2617715B1 (fr) * 1987-07-07 1990-08-31 Transgene Sa Vecteur viral et adn recombinant codant pour une ou des proteines de surface (ha et/ou f) d'un morbillivirus, culture cellulaire infectee, proteines obtenues, vaccin et anticorps obtenus
DE10399031I1 (de) * 1987-08-28 2004-01-29 Health Research Inc Rekombinante Viren.
FR2632863B2 (fr) * 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
JPH01218590A (ja) * 1988-02-29 1989-08-31 Toa Nenryo Kogyo Kk 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン

Also Published As

Publication number Publication date
GB2283021B (en) 1995-07-05
ITMI913092A0 (it) 1991-11-20
DE4192786T1 (de) 1994-01-13
IT1252687B (it) 1995-06-23
AU1253892A (en) 1992-06-11
NL9120026A (nl) 1993-09-01
NL195095C (nl) 2004-01-21
CA2096633A1 (en) 1992-05-21
JP3824619B2 (ja) 2006-09-20
IE68404B1 (en) 1996-06-12
NL195058C (nl) 2003-07-01
ITMI913092A1 (it) 1993-05-20
JPH06502996A (ja) 1994-04-07
IE71643B1 (en) 1997-02-26
GB2264949A (en) 1993-09-15
BE1005908A5 (fr) 1994-03-08
CH683921A5 (fr) 1994-06-15
NL9900036A (nl) 2003-10-01
FR2669346B1 (fr) 1995-07-21
GB2264949B (en) 1995-07-05
DE4192786B4 (de) 2006-08-24
FR2669346A1 (fr) 1992-05-22
GB2283021A (en) 1995-04-26
GB9500214D0 (en) 1995-03-01
JP2005040129A (ja) 2005-02-17
GB9309414D0 (en) 1993-07-14
WO1992008789A1 (en) 1992-05-29
IE913960A1 (en) 1992-05-20

Similar Documents

Publication Publication Date Title
KR970011149B1 (ko) 재조합 아비폭스 바이러스
CA1341234C (en) Recombinant fowlpox virus
JP3602844B2 (ja) 遺伝子操作したワクチン菌株
JP4108742B2 (ja) ポックスウイルス−イヌジステンパーウイルス（ｃｄｖ）組み換え体類および組成物類および前記組み換え体類を用いる方法
JP4140862B2 (ja) 組換体ポックスウイルス−狂犬病組成物および組合せ組成物並びに使用
Guo et al. Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals
JP3617668B2 (ja) 麻疹ウイルス組換え体ポックスウイルスワクチン
US7144578B2 (en) Poxvirus-rabies recombinants and compositions and methods employing the recombinants
Bertagnoli et al. Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein
JP2007082551A (ja) 組換えポックスウイルス−カリシウイルス［ウサギ出血疾患ウイルス（ｒｈｄｖ）］組成物および使用
US5503834A (en) Measles virus recombinant poxvirus vaccine
US5759841A (en) Immunological composition of measles virus utilizing recombinant poxvirus
JPH07503843A (ja) マレック病ウイルス組換えポックスウイルスワクチン
AU699903B2 (en) Measles virus recombinant poxvirus vaccine
CA1341403C (en) Recombinant a vipox virus
KR100263279B1 (ko) Ｔｒｏｖａｃ 계두 바이러스 재조합체 및 그것의 사용
AU720448B2 (en) Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
IE60309B1 (en) Recombinant viruses, vaccines containing them and in vitro cell cultures thereof

Legal Events

Date Code Title Description
A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20040618

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20040819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20041005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20041104

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071119

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081119

Year of fee payment: 4

LAPS Cancellation because of no payment of annual fees